IN2014MN01868A - - Google Patents

Info

Publication number
IN2014MN01868A
IN2014MN01868A IN1868MUN2014A IN2014MN01868A IN 2014MN01868 A IN2014MN01868 A IN 2014MN01868A IN 1868MUN2014 A IN1868MUN2014 A IN 1868MUN2014A IN 2014MN01868 A IN2014MN01868 A IN 2014MN01868A
Authority
IN
India
Prior art keywords
adamts
recognise
bind
nucleic acid
production
Prior art date
Application number
Other languages
English (en)
Inventor
Riccardo Chiusaroli
Michela Visintin
Gianfranco Caselli
Lucio Claudio Rovati
Original Assignee
Rottapharm Biotech Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Biotech Srl filed Critical Rottapharm Biotech Srl
Publication of IN2014MN01868A publication Critical patent/IN2014MN01868A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1868MUN2014 2012-04-13 2013-04-12 IN2014MN01868A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12164107.0A EP2650310B1 (fr) 2012-04-13 2012-04-13 Anticorps anti-ADAMTS-5, dérivés et utilisations correspondantes
PCT/EP2013/057649 WO2013153189A1 (fr) 2012-04-13 2013-04-12 Anticorps anti-adamts-5, ses dérivés et utilisations

Publications (1)

Publication Number Publication Date
IN2014MN01868A true IN2014MN01868A (fr) 2015-07-03

Family

ID=48083198

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1868MUN2014 IN2014MN01868A (fr) 2012-04-13 2013-04-12

Country Status (19)

Country Link
US (1) US9631029B2 (fr)
EP (2) EP2650310B1 (fr)
JP (1) JP2015518476A (fr)
KR (1) KR20150003278A (fr)
CN (1) CN104245737B (fr)
AR (1) AR090668A1 (fr)
AU (1) AU2013246880B2 (fr)
CA (1) CA2869031A1 (fr)
DK (1) DK2650310T3 (fr)
ES (1) ES2588484T3 (fr)
HK (1) HK1202296A1 (fr)
HU (1) HUE031089T2 (fr)
IN (1) IN2014MN01868A (fr)
MX (1) MX2014012295A (fr)
PL (1) PL2650310T3 (fr)
PT (1) PT2650310T (fr)
RU (1) RU2014145536A (fr)
TW (1) TWI579302B (fr)
WO (1) WO2013153189A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
GB201610056D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610055D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
IT201800003818A1 (it) * 2018-03-21 2019-09-21 Fond Per Listituto Oncologico Di Ricerca Ior Nuovi farmaci prosenescenza
FI129515B (en) 2020-11-06 2022-03-31 Salarusta Oy FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY
AU2021399788A1 (en) 2020-12-15 2023-08-03 Lakefront Biotherapeutics Nv Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione
CN116256518B (zh) * 2023-02-24 2025-07-04 北京爱德诺生物科技有限公司 一种肿瘤诊断标志物及其诊断试剂盒和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5484590A (en) * 1993-09-09 1996-01-16 La Jolla Cancer Research Foundation Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family
WO2000053774A2 (fr) 1999-03-08 2000-09-14 Neurocrine Biosciences, Inc. Metalloproteinases et leurs procedes d'utilisation
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
BR0318625A (pt) * 2003-12-04 2006-10-31 Wyeth Corp biaril sulfonamidas e métodos para usar as mesmas
SG177288A1 (en) 2009-07-02 2012-02-28 Glaxo Group Ltd Polypeptides and method of treatment

Also Published As

Publication number Publication date
DK2650310T3 (en) 2016-09-12
WO2013153189A1 (fr) 2013-10-17
EP2650310B1 (fr) 2016-06-08
EP2650310A1 (fr) 2013-10-16
US20150056210A1 (en) 2015-02-26
RU2014145536A (ru) 2016-06-10
US9631029B2 (en) 2017-04-25
AU2013246880B2 (en) 2016-04-21
CA2869031A1 (fr) 2013-10-17
CN104245737A (zh) 2014-12-24
HK1202296A1 (en) 2015-09-25
JP2015518476A (ja) 2015-07-02
TW201402606A (zh) 2014-01-16
EP2836516B1 (fr) 2017-07-26
PT2650310T (pt) 2016-09-01
CN104245737B (zh) 2017-04-05
TWI579302B (zh) 2017-04-21
HUE031089T2 (en) 2017-06-28
PL2650310T3 (pl) 2017-01-31
AU2013246880A1 (en) 2014-10-16
MX2014012295A (es) 2014-11-10
EP2836516A1 (fr) 2015-02-18
AR090668A1 (es) 2014-11-26
KR20150003278A (ko) 2015-01-08
ES2588484T3 (es) 2016-11-03

Similar Documents

Publication Publication Date Title
PH12014502527B1 (en) St2 antigen binding proteins
ZA202308845B (en) Cx3cr1-binding polypeptides
CY1122978T1 (el) Αντισωματα εναντι-vla-4
EA201492101A1 (ru) Антитела против fcrn
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
IN2014DN03451A (fr)
MX358739B (es) Proteinas de union a amiloide beta.
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2012011934A (es) Proteinas de union a amiloide beta.
PH12016500275B1 (en) Antibodies
MY178142A (en) Anti-phf-tau antibodies and their uses
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
IN2014DN08011A (fr)
PH12015501687A1 (en) Novel binding proteins from pcsk9
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
SMT201800620T1 (it) Anticorpi che legano la proteina di riconoscimento dei peptidoglicani 1
WO2014151834A3 (fr) Procédés et compositions liés aux protéines de liaison à un antigène anti-ccr7
WO2013122544A3 (fr) Anticorps monoclonaux humains neutralisant il-1β
MX2016005982A (es) Anticuerpos anti-ligando 17 de quimiocinas (motivo c-c).
HK1223374A1 (zh) 抗fviii抗体或其用途